A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia

Leukemia

Volumn 24, Issue 1, 2010, Pages 222-226

  Spaner, D E ^a,b   Shi, Y ^a   White, D ^a   Shaha, S ^a   He, L ^c   Masellis, A ^d   Wong, K ^b   Gorczynski, R ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Cancer Vaccine Program   (Canada)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; COMPOUND 852A; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; PREDNISONE; RITUXIMAB; TOLL LIKE RECEPTOR 7 AGONIST; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HOT FLUSH; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; LEUKEMIA RELAPSE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SPLENECTOMY; TREATMENT RESPONSE;

EID: 74249084935     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.195     Document Type: Letter

References (9)

1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of CLL. Blood 2008; 111: 5446-5456.
2. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20: 504-511.
3. Spaner DE, Foley R, Galipeau J, Bramson J. Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene 2008; 27: 208-217.
4. Shi Y, White D, He L, Miller RL, Spaner DE. TLR-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007; 67: 1823-1831.
5. Spaner DE, Masellis A. TLR agonists in the treatment of CLL. Leukemia 2007; 21: 53-60.
6. Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V et al. An exploratory study of systemic administration of the TLR-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008; 14: 856-864.
7. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S et al. First in human phase I trial of 852A, a novel systemic TLR-7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007; 13: 7119-7125.
8. Raphael B, Andersen JW, Silber R, Oken M, Moore D, Bennett J et al. Comparison of chlorambucil and prednisone versus cyclophos-phamide, vincristine, and prednisone as initial treatment for CLL. J Clin Oncol 1991; 9: 770-776.
9. Tomic J, White D, Shi Y, Mena J, Hammond C, He L et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006; 176: 3830-3839.